Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:03:32.330Z.
Calculation as of: 2026-10-06T18:03:32.330Z.
Quote observation: 2026-10-06T18:00:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85bde4aa0a662304b106d2bd805683c4a4a85ed0eecab472c1d88190f6ac555e
PEG RATIO
N/A
Market Cap
$1.44B
PEG Ratio
N/A
TTM Avg
1.94
3Y Avg
1.77
5Y Avg
2.38
Market Cap
$1.45B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.43B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | N/A | 1.94 | 1.77 | 2.38 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 4.48 | 2.78 | 1.98 | 1.98 |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
